Present situation of the sphinx in Tianjin

Recently, Tianjin News reported the R&D work of Sphinx Pharmaceutical R&D (Tianjin) Co., Ltd., a member of Tianjin Shanxi Chamber of Commerce (co-organizer of China Jinshang Club).

It is reported that at present, Binhai New Area has gathered 1500 innovative drugs, modern Chinese medicine, synthetic biology, medical devices, pharmaceutical biotechnology and other enterprises, giving play to the industrial agglomeration effect. Binhai New Area is driven by leading enterprises, creating an innovative consortium. The leading enterprise Sphinx provides the whole chain service from preclinical research to drug listing for more than 20 pharmaceutical companies in the city.

With more and more service enterprises, Sphinx urgently needs to improve the energy efficiency of professional testing, but it takes a long time to buy a lot of new equipment and send it to professional testing institutions. With the help of the industrial map of enterprises in the Economic Development Zone formulated and published at the beginning of the year, Sphinx directly found Hanmeng testing, and both parties cooperated with the team to realize the whole process of R&D testing. Yao, chairman of Sphinx Pharmaceutical R&D (Tianjin) Co., Ltd. said: "In the process of R&D, they help to find and communicate any problems in time, which is more efficient and faster. The output value can reach1.50 billion to about 2 billion. "

Sphinx Pharmaceutical (Tianjin) Co., Ltd. was founded in 2009 by Dr. Yao who studied in the United States, providing R&D and production outsourcing services for innovative drugs. Focus on the chemical synthesis of innovative pharmaceutical intermediates and APIs in China. After ten years' efforts, the company has an experienced and stable R&D and production team, formed the unique technology of Sphinx, accumulated a lot of R&D and production experience, and won the recognition and praise of customers. The company has successfully completed nearly 3,000 drug screening research and development projects and more than 200 clinical projects, some of which have been commercialized and formed a high reputation in the industry.

The company has 26 invention patents and many unique technologies, and has been rated as a national high-tech enterprise since 20 12. With more than 10000 square meters of R&D center and two production bases, it is very competitive in the industry. 20 13 and 20 16 were awarded the titles of "the most potential enterprise" and "the most growing entrepreneurial enterprise" among the 100 enterprises in China Overseas Students Pioneer Park respectively. 20 16 was listed on the new third board, and many well-known investment institutions participated in it; In 20 18, it was selected as "Gazelle Enterprise" in Tianjin Development Zone and recognized as "Science and Technology Enterprise" by Tianjin Science and Technology Bureau. In 2020, the third batch of national science and technology small and medium-sized enterprises will be put into storage.

The company studied hard and accumulated a lot. Through the accumulation of previous projects, it has entered a new stage of rapid development, and its sales revenue has doubled year after year. While steadily expanding the production scale, the company constantly strengthens the core competitiveness of technology, adheres to the concept of "safety first" and "environmental protection-oriented", and constantly develops core technologies such as green environmental protection and continuous automated production.

In order to meet the rapid development of the company's business, the company has started to build a 14000 square meter R&D headquarters in TEDA, Tianjin, and is preparing to build a new production base for pharmaceutical intermediates and APIs.

Sphinx, which has been deeply involved in the field of pharmaceutical outsourcing, has won the trust and affirmation of customers with its high standard, high quality and efficient service, and has established long-term cooperative relations with many well-known pharmaceutical companies at home and abroad, which has been well received by customers and partners.